Intellia Q2 net loss narrows to $101.3M; Phase 3 enrollment ahead; CMO to retire in 2026

Intellia Therapeutics, Inc.

2025-Q2 EPS reported -$2.08 revenue$30,872,000

Net loss $101.3M in Q2 2025 vs $147.0M a year ago; collaboration revenue $14.2M (up from $6.9M).
Cash, equivalents and marketable securities $630.5M as of June 30, expected to fund ops into H1 2027.
Phase 3 MAGNITUDE (ATTR-CM) enrollment ahead; study expanded from 765 to ~1,200 patients.
Phase 3 HAELO (HAE) randomization expected to complete in Q3 2025; BLA submission targeted H2 2026.
CMO Dr. David Lebwohl to retire effective Aug 7, 2026; will continue in role until successor appointed.

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.